Rand Eye Institute | Deerfield Beach, FL
Status and phase
Conditions
Treatments
About
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Full description
Part 1 of the trial will be a multi-center, open label safety and dose escalation study with a potential enrollment of 30 participants having geographic atrophy (GA) secondary to macular degeneration. They will receive a single intravitreal injection of study drug (AVD-104) and will be followed for 3 months for safety observation. They will have both aqueous humor and peripheral blood drawn for pharmacokinetic and pharmacodynamic evaluations.
Part 2 will be a multi-center, double masked, randomized trial to evaluate the treatment effect of AVD-104 on participants with geographic atrophy secondary to macular degeneration. Participants will be randomized to high dose AVD-104, low dose AVD-104, or active comparator (avacincaptad). The primary endpoint will be the difference in the rate of growth of the GA area as measured by fundus autofluorescence.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Part 1:
Part 2:
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
Part 1 and 2
Primary purpose
Allocation
Interventional model
Masking
300 participants in 4 patient groups
Loading...
Central trial contact
Keri Marchitto, MA; David Callanan, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal